• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

    10/25/24 9:39:32 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IPSC alert in real time by email
    SC 13G/A 1 ff4031810_13ga1-century.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     


    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     
     


    Century Therapeutics Inc.
    (Name of Issuer)

    Common Stock, par value $0.0001
    (Title of Class of Securities)

    15673T100
    (CUSIP Number)

    October 10, 2024
    (Date of Event which Requires Filing of this Statement)
     
     


         Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)
    ____________
    *    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

                 The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No.: 15673T100
    13G
     Page 2 of 12 Pages


    1
    NAMES OF REPORTING PERSONS
     
     
    Boxer Capital, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     



    CUSIP No.: 15673T100
    13G
     Page 3 of 12 Pages


    1
    NAMES OF REPORTING PERSONS
     
     
    Boxer Asset Management Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Bahamas
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
     
     
     
     
     

     
    CUSIP No.: 15673T100
    13G
     Page 5 of 12 Pages


    1
    NAMES OF REPORTING PERSONS
     
     
    Joe Lewis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United Kingdom
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No.: 15673T100
    13G
     Page 6 of 12 Pages


    1
    NAMES OF REPORTING PERSONS
     
     
    MVA Investors, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No.: 15673T100
    13G
     Page 7 of 12 Pages


    1
    NAMES OF REPORTING PERSONS
     
     
    Aaron I. Davis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    3,174,603
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    3,174,603
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,174,603
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    3.7%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     
     

    CUSIP No.: 15673T100
    13G
     Page 8 of 12 Pages


    1
    NAMES OF REPORTING PERSONS
     
     
    Boxer Capital Management, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    3,174,603
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    3,174,603
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,174,603
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    3.7%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO; IA
     
     
     
     
     

     
    This Amendment No. 1 (“Amendment No. 1”) amends and supplements the statement on Schedule 13G initially filed on April 22, 2024 (the “Original Filing”) by Boxer Capital, LLC (“Boxer Capital”), Boxer Asset Management Inc. (“Boxer Management”), Joe Lewis, Aaron I. Davis and MVA Investors, LLC (“MVA Investors”) regarding the Common Stock of Century Therapeutics, Inc. On October 10, 2024, Boxer Capital entered into an investment management agreement (the “IMA”) with Boxer Capital Management LLC (“BCM”), a registered investment advisor controlled by Mr. Davis. Pursuant to the IMA, Boxer Capital has delegated exclusive voting and investment power over its investment portfolio to BCM. Consequently, BCM has acquired beneficial ownership of the securities held in Boxer Capital’s investment portfolio and, without reflecting any change in its economic interest in such securities, Boxer Capital has thereby ceased to beneficially own the securities held in its investment portfolio, including shares of Common Stock. To the extent applicable, the Original Filing, as hereby amended, is hereby adopted by BCM as its original filing on Schedule 13G regarding the Common Stock. The Original Filing, as amended, remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 1. Capitalized terms used and not defined in this Amendment No. 1 have the meanings set forth in the Original Filing, as amended. Boxer Capital, Boxer Management, Mr. Lewis, MVA Investors, Mr. Davis and BCM report herein that they have ceased to beneficially own more than 5% of the outstanding shares of Common Stock.
    Item 2(a): Name of Person Filing
    Item 2(a) is hereby amended and restated to read as follows:

    This Schedule 13G is jointly filed by Boxer Capital, Boxer Management, Mr. Lewis, MVA Investors, Mr. Davis and BCM (collectively, the “Reporting Persons”).

    Boxer Management is the managing member and majority owner of Boxer Capital. Mr. Lewis is the sole indirect owner of and controls Boxer Management. MVA Investors is the independent, personal investment vehicle of certain employees of BCM. BCM is a registered investment advisor, providing investment management services to Boxer Capital. Mr. Davis is the Managing Member of BCM and is a member of and has voting and dispositive power over securities beneficially held by MVA Investors and BCM. With his immediate family, Mr. Davis indirectly owns the membership interests in BCM.

    Item 2(b): Address of Principal Business Office or, if None, Residence

    Item 2(b) is hereby amended and restated to read as follows:

    The principal business address of Boxer Capital, MVA Investors, Mr. Davis and BCM is: 12860 El Camino Real, Suite 300, San Diego, CA 92130. The principal business address of Boxer Management and Mr. Lewis is: Albany Financial Center, Suite 207, Lewis Drive, N7776, New Providence, Bahamas.

    Item 2(c): Citizenship

    Item 2(c) is hereby amended and restated to read as follows:

    Boxer Capital, MVA Investors and BCM are limited liability companies organized under the laws of Delaware. Boxer Management is a Bahamian international business company. Mr. Lewis is a citizen of the United Kingdom. Mr. Davis is a citizen of the United States of America.

    Item 4: Ownership

    Item 4 is hereby amended and restated to read as follows:


    (a)
    Amount beneficially owned: BCM and Mr. Davis beneficially own 3,174,603 shares of Common Stock. The Reporting Persons beneficially own, in the aggregate, 3,174,603 shares of Common Stock.
    (b)
    Percent of class: All percentages of beneficial ownership set forth herein are based on 84,715,961 shares of Common Stock reported outstanding on August 1, 2024 in the Form 10-Q filed by the Issuer with the Securities and Exchange Commission on August 8, 2024. The number of shares of Common Stock beneficially owned by the Reporting Persons in the aggregate represents 3.7% of the Issuer’s outstanding shares of Common Stock.
    (c)
    Number of shares as to which such person has:
    (i)
    sole power to vote or to direct the vote: None of the Reporting Persons has sole power to vote or to direct the vote of any shares of Common Stock.
    (ii)
    shared power to vote or to direct the vote: BCM and Mr. Davis have shared power to vote or to direct the vote of 3,174,603 shares of Common Stock.
    (iii)
    sole power to dispose or to direct the disposition of: None of the Reporting Persons has sole power to dispose or to direct the disposition of any shares of Common Stock.
    (iv)
    shared power to dispose or to direct the disposition of: BCM and Mr. Davis have shared power to dispose or to direct the disposition of 3,174,603 shares of Common Stock.
    Item 5: Ownership of Five Percent or Less of a Class
    With respect to the Reporting Persons:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.
    Item 6: Ownership of More than Five Percent on Behalf of Another Person

    Item 6 is hereby amended and restated to read as follows:

    Other than as may result from indirect interests of investors in Boxer Capital and MVA Investors, no persons other than the Reporting Persons have the right to receive or the power to direct the receipt of dividends, or proceeds of sale of the securities disclosed herein.

    Item 10: Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
    Exhibits
     
     
    2
     
    Joint Filing Agreement, dated October 25, 2024, among the Reporting Persons.
      

    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated:  October 25, 2024

     
    BOXER CAPITAL, LLC
     
     
     
     
     
    By:
     /s/ Aaron I. Davis
     
     
     
    Name:  
    Aaron I. Davis
     
     
    Title:
    Authorized Signatory
     
     
     
     
    BOXER ASSET MANAGEMENT INC.
     
     
     
     
     
    By:
     /s/ Paul Higgs
     
     
     
    Name:
    Paul Higgs
     
     
    Title:
    Director
     
     
     
     
    JOSEPH C. LEWIS
     
     
     
     
     
     /s/ Joseph C. Lewis
     
      
    Joseph C. Lewis, Individually
     
     
     
     
     
    MVA INVESTORS, LLC
     
         
     
    By:
     /s/ Aaron I. Davis  
       
    Name:
    Aaron I. Davis
       
    Title:
    Authorized Signatory
         
     
    AARON I. DAVIS 
     
         
     
     /s/ Aaron I. Davis
     
      
    Aaron I. Davis, Individually
     
     
     
    BOXER CAPITAL MANAGEMENT, LLC
     
         
     
    By:
     /s/ Aaron I. Davis  
       
    Name:
    Aaron I. Davis
       
    Title:
    Managing Member

    Get the next $IPSC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IPSC

    DatePrice TargetRatingAnalyst
    8/8/2024$6.00Buy
    Rodman & Renshaw
    8/28/2023$28.00 → $5.00Overweight → Neutral
    JP Morgan
    12/27/2022$19.00Buy
    Chardan Capital Markets
    10/31/2022$15.00Buy
    Guggenheim
    10/10/2022$28.00Buy
    Canaccord Genuity
    5/23/2022$27.00Buy
    H.C. Wainwright
    5/12/2022Mkt Perform
    William Blair
    11/19/2021$33.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $IPSC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

      PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in Barcelona, Spain. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer. Details of the presentations are as follows: Abstract Number: 1380Title: C

      5/28/25 4:01:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies Presentations at ASGCT 28th Annual Meeting highlight preclinical pipeline anchored by advanced iPSC-derived 'tunable' CD4+/CD8+ ab T cells and Allo-Evasion™ 5.0 technology PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripoten

      5/15/25 4:01:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

      PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer. Details of the presentations are as follows:

      4/28/25 4:30:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Century Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $6.00

      8/8/24 10:22:51 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics downgraded by JP Morgan with a new price target

      JP Morgan downgraded Century Therapeutics from Overweight to Neutral and set a new price target of $5.00 from $28.00 previously

      8/28/23 7:15:43 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital Markets initiated coverage on Century Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $19.00

      12/27/22 7:45:12 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Financials

    Live finance-specific insights

    See more
    • Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

      - Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase 1 ELiPSE-1 trial in relapsed/refractory (R/R) B-cell lymphoma to be presented at American Society for Clinical Oncology (ASCO) Annual Meeting - Ended 1Q24 with cash, cash equivalents, and invest

      5/9/24 7:30:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

      – Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – – Preliminary clinical data demonstrate six-month durable complete response in Dose Level 1 in a single patient following multiple cycles of CNTY-101 without lymphodepletion – – Pharmacokinetic data suggests CNTY-101 exposure may be maintained upon administration of additional cycles without lymphodepletion due to lack of observed allo-rejection – –   Company to host conference call on Monday, December 11 at 7:30 AM PT/10:30 AM ET to review ASH data including additional clinical results from Dose Level 1

      12/9/23 12:00:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

      PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company's lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas. In addition to updated preliminary clinical data as of a more re

      12/6/23 7:30:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Century Therapeutics Inc.

      SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)

      11/27/24 6:51:58 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

      SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

      11/14/24 5:46:35 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

      SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

      11/14/24 4:08:17 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Leadership Updates

    Live Leadership Updates

    See more

    $IPSC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

      - Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion - - Received investigational new drug (IND) clearance for CNTY-101 for the treatment of systemic lupus erythematosus (SLE); On track to initiate Phase 1 CALiPSO-1 clinical trial in the first half of 2024 - - Six posters to be presented at upcoming AACR Annual Meeting 2024 highlighting Century's end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein en

      3/14/24 7:30:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer

      - Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry - Brent Pfeiffenberger, Pharm.D., MBA PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer and member of the Board, effective December 4, 2023. A proven leader with over 20 years of global experience across the healthcare industry, Dr. Pfeiffenberger most recently served as Chief Operating Officer at Neogene Therapeutics, a who

      11/9/23 7:00:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Pfeiffenberger Brent sold $16,135 worth of shares (29,552 units at $0.55), decreasing direct ownership by 2% to 1,682,258 units (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      5/20/25 4:19:34 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operations Officer Farid Adrienne sold $563 worth of shares (1,024 units at $0.55), decreasing direct ownership by 0.41% to 250,693 units (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      5/7/25 4:38:50 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP Finance & Operations Carr Douglas sold $162 worth of shares (295 units at $0.55), decreasing direct ownership by 0.07% to 410,886 units (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      5/7/25 4:38:25 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Century Therapeutics Inc.

      SCHEDULE 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

      5/15/25 4:27:17 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Century Therapeutics, Inc. (0001850119) (Filer)

      5/15/25 4:15:54 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Century Therapeutics Inc.

      10-Q - Century Therapeutics, Inc. (0001850119) (Filer)

      5/15/25 4:15:56 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Quimi Daphne bought $7,657 worth of shares (5,000 units at $1.53) (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      9/16/24 4:18:18 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care